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Murine P-glycoprotein on stromal vessels mediates
multidrug resistance in intracerebral human glioma
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Summary Human glioma usually shows intrinsic multidrug resistance because of the blood-brain barrier (BBB), in which membrane-
associated P-glycoprotein (P-gp), encoded by the human multidrug resistance gene MDR1, plays a role. We studied drug sensitivity to
vincristine (VCR), doxorubicin (DOX) and nimustine (ACNU) in both intracerebrally and subcutaneously xenotransplanted human glioma. We
examined the levels of MDR1 and murine mdr3gene expression in the xenografts by reverse transcriptase polymerase chain reaction and the
localization of P-gp by immunohistochemistry. Six of seven subcutaneously transplanted xenografts (scX) were sensitive to the above three
drugs. In contrast, all three intracerebrally transplanted human glioma xenografts (icX) were resistant to P-gp-mediated drugs VCR and DOX,
but were sensitive to the non-P-gp-mediated drug ACNU. Neither icX nor scX showed any MDR1 expression. Intracerebrally transplanted
human glioma xenografts showed an increased level of murine mdr3 gene expression, whereas scX showed only faint expression. The
localization of P-gp was limited to the stromal vessels in icX by immunohistochemistry, whereas scX expressed no P-gp. Ourfindings suggest
that the P-gp expressed on the stromal vessels in icX is a major contributing factor to multidrug resistance in human glioma in vivo.
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Total removal ofglioma is clinically difficult as the borders are ill
defined. In addition, glioma shows intrinsic multidrug resistance
to anti-cancer agents, and chemotherapy for glioma is thus unsuc-
cessful (Edwards et al, 1980; Komblith et al, 1988). Various mech-
anisms, including the blood-brain barrier (BBB), have been
considered to be involved in the multidrug resistance ofglioma.
Certain ultrastructural features, including the absence of fenes-
tration and the presence oftightjunctions, are considered to char-
acterize the BBB (Reese et al, 1967; Long, 1970). However, it has
been reported (Levin, 1980) that hydrophobic anti-cancer agents
such as vinca alkaloids and doxorubicin (DOX) do not easily enter
the brain, although other hydrophobic molecules readily passed
through the BBB. Thus, it appears that morphological BBB struc-
tures cannot completely explain the multidrug resistance in human
glioma.
Some studies have indicated that the membrane-associated
protein P-glycoprotein (P-gp), encoded by human multidrug resis-
tance geneMDRJ, is related to the multidrug resistance phenotype
in human neoplasms (Chen et al, 1986; 1990; Gros et al, 1986),
and that P-gp is a component of the BBB in the normal brain
(Tatsuta et al, 1992). We have revealed that, in human glioma,
P-gp is expressed not on the tumour cells but on the capillary
blood vessels as determined by immunohistochemical and molec-
ular biological methods (Tanaka et al, 1994).
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In our other previous report, almost all the glioma xenografts
subcutaneously transplanted in the nude mice were curiously
sensitive to P-gp-mediated anti-cancer drugs (vincristine, VCR
and DOX) without MDRJ expression (Abe et al, 1994a), whereas
these drugs are usually ineffective in clinical cases.
In this study, we performed intracerebral (icX) and subcutaneous
(scX) transplantation ofhuman glioma into nude mice to analyse the
differences in chemosensitivity to anti-cancer drugs between clinical
glioma and scX. We studied the chemosensitivity in vivo and the
levels of expression ofhuman MDR] and murine mdr3 (also called
mdrla) gene in thesegliomaxenografts. We alsoexamined the local-
ization ofP-gp in these glioma xenografts by immunohistochemistry.
We discuss here the mechanisms ofintrinsic multidrug resistance of
glioma in relation to stromal endothelial P-gp expression in vivo.
MATERIALS AND METHODS
Human glioma xenografts and cell lines
Seven human glioma xenografts were established from primary
glioma specimens obtained from patients in whom there had been
no preceding chemotherapy (Table 1). The xenografts were main-
tained by serial subcutaneous transplantation in nude mice
(BALB/c-nu/nu, Clea Japan, Tokyo). The xenografts were used at
10-20 passages. We obtained xenografts from mice after they had
been deeply anaesthetized with chloroform. The drug-sensitive
epidermoid carcinoma cell line KB3-1 and its resistant derivative
KB8-5 were cultured in Dulbecco's modified Eagle minimal essen-
tial medium supplemented with 5% fetal bovine serum at 37°C in a
fully humidified 95% air, 5% carbon dioxide atmosphere.
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Table 1 Patient characteristics of primary glioma used for establishment of
xenografts
Xenograft Age Sex Histology Clinical therapya
Epe-1 10 M EPE Surg
GL-1 3 M EPE Surg+ Ra
GL-2 32 M GM Surg+ Ra
GL-3 47 M GM Surg
GL-5 50 M GM Surg
GL-7 67 F GM Surg
GL-8 10 M GM Surg
EPE, ependymoma; GM, glioblastoma multiforme; Surg, surgical removal;
Ra, radiation therapy. aChemotherapy was not performed on these patients.
In vivo chemosensitivity test
DOX (Kyowa Hakkoh Kogyo, Tokyo), VCR (Shionogi, Osaka)
and ACNU (Sankyo, Tokyo) were purchased from the sources
shown. All drugs were dissolved in saline and used for in vivo
chemosensitivity tests.
We performed in vivo chemosensitivity tests on seven scX
(Epe-1, GL-1, GL-2, GL-3, GL-5, GL-7, and GL-8), according to
the procedures reported previously (Inaba et al, 1989; Abe et al,
1996a,b). The nude mice were used at 6-8 weeks ofage in accor-
dance with the animal care guidelines of the Central Institute for
Experimental Animals. Six female mice (BALB/c-nu/nu) bearing
xenografts (tumour volume: 100-300 mm3) were given the
maximum tolerated dose (MTD) of VCR (1.6 mg kg-') or DOX
(12 mg kg-'). Growth of the tumour xenografts was measured
by the relative tumour volume (RV), which was expressed as
RV = V,4/V0, where V14 is the tumour volume at day 14 and V0 is
the initial tumour volume when the treatment was started (day 0).
The effects of the drugs are represented by RV of the xenografts,
and the T/C% values were defined as the ratio ofRV ofthe treated
tumour xenografts to controls. Evaluation as 'sensitive' was
defined based on statistical significance determined by the
Mann-Whitney U-test (P < 0.01, one-sided).
We also examined in vivo chemosensitivity in three icX (GL-2,
GL-5, and GL-8), according to the previously reported method
(Ausman et al, 1970; Shapiro et al, 1979; 1981). When the animals
showed severe wasting and were apparently moribund owing to
intracerebral tumour growth, they were not observed further and
the day ofsacrifice was recorded to estimate life span according to
the UKCCCR guidelines (Workman et al, 1988). Surviving
animals were sacrificed at the end ofthe experiment and sectioned
formicroscopic examination oftumour foci. The gliomaxenograft
specimens were removed from nude mice that had been deeply
anaesthetized, and were immediately suspended in Ham's FlO
culture medium. For intracerebral inoculation, 1 x 106 cells
(in 0.025 ml) were injected percutaneously into the right cerebral
hemisphere of nude mice using a 27-gauge needle. Six nude mice
bearing the icX were intravenously treated with the MTD of each
drug 5 days after inoculation. Drug sensitivity was represented by
determining the percentage increase in lifespan (ILS) ofthe treated
nude mice compared with controls. The significance ofdifferences
ofILS between treated and control mice was statistically tested by
Student's t-test.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
The levels of expression ofMDRJ transcripts were determined by
the modified reverse transcriptase polymerase chain reaction
(RT-PCR) procedure as described previously (Noonan et al, 1990;
Abe et al, 1994b). Normal human tissues (brain and kidney) were
obtained by major surgery after obtaining the patients' informed
consent. RT-PCR amplified a 243-bp fragment of MDR] cDNA.
We estimated MDR] expression level in comparison with that of
the housekeeping gene P2-microglobulin (IB2m).
We also prepared sets of specific primers for murine mndr3
(#M; sense, CATGGCTGGATCAGTGT'TTCTAGA, residues
3391-3415; antisense, GCAGTGAGTCGATGAACTGGTGGA,
residues 3585-3608), and for murine ,B2m (#N; sense, GCAAG-
GACTGGTCT'l'CTATA, residues 3144-3164; antisense, GCAT-
GACAGTATGGCCGAGCC, residues 3223-3243) (Pames et al,
1982; Gros et al, 1988). RT-PCR with these amprimers revealed a
218-bp segment of murine mdr3. The PCR products blotted on a
membrane (Zeta Probe, BioRad) were detected by hybridization
with synthetic oligonucleotide probes (GCCGTGTCTCATGAG-
GAGATTGTG, residues 3518-3541, for#M; CTGATACATACGC-
CTGCAGAG, residues 3217-3240, for#N) labelled with 32p.
Immunohistochemistry
P-gp-positive tumour cells were analysed immunohistochemically
with the anti-P-gp polyclonal antibody Ab-I (Oncogene Science)
(Toth etal, 1994; Abeetal, 1996a). Tumoursections were incubated
with Ab-1, peroxidase-conjugated F(ab')2 of donkey anti-rabbit
IgG (Amersham), rabbit monoclonal peroxidase-anti-peroxidase
complex (Dako) and peroxidase-conjugated F(ab')2 fragments. The
products were visu'alized with 3,3'-diaminobenzidine tetrahydro-
chloride.
RESULTS
In vivo chemosensitivity test
Table 2 summarizes the growth features ofthe scX, including rela-
tive tumour volume, T/C%, and Mann-Whitney U-test results
(P < 0.01, one-sided). All seven scX showed T/C% values signifi-
cantly less than 35%, and were thus considered to be sensitive to
VCR and ACNU. Six of seven scX were also sensitive to DOX
(T/C% < 32%). Only one scX (GL-5) showed a relatively high
T/C% value to DOX (66%). The glioma scX showed high
response rates of 100%, 100% and 86% to VCR, ACNU and DOX
respectively. The maximum volume of tumour xenograft did not
exceed 10% ofthe weight ofthe mouse (data not shown).
The drug sensitivity of icX is shown in Table 3. None of the
three icX treated with VCR and DOX showed any significant
elongation of the ILS (less than 55%), whereas the icX treated
with ACNU showed remarkably high values for the ILS.
Significant effects of ACNU on the glioma icX were also
confirmed by statistical analysis by Student's t-test (P < 0.01).
Expression of MDR1
The humanMDRJ-specific amprimers did notamplify murine mdr
cDNA from normal murine tissues (brain, heart, lung, kidney,
liver, spleen), although the sense and antisense primers showed
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Table 2 In vivo chemotherapy of subcutaneously transplanted glioma
xenograft (scX)
Xenograft Relative tumour volume' T/Cb U-testc
drug (%)
Control Treated
VCR
Epe-1 6.08 ± 2.33 0.61 ± 0.23 10 +
GL-1 3.59 ± 0.57 0.37 ± 0.55 10 +
GL-2 8.48±3.04 0.54±0.12 6 +
GL-3 7.59±3.40 0.33±0.14 4 +
GL-5 4.68± 1.19 0.43±0.17 9 +
GL-7 12.29±4.13 0.09±0.02 1 +
GL-8 7.25+±1.99 0.21 ±0.11 3 +
DOX
Epe-1 6.08 ± 2.33 1.73 ± 0.34 28 +
GL-1 3.04 ± 0.92 0.97 ± 0.41 32 +
GL-2 8.48 ± 3.04 2.42 ± 0.40 29 +
GL-3 7.59±3.40 1.29±0.18 17 +
GL-5 4.68± 1.19 3.10±0.94 66 -
GL-7 14.31 ±4.35 1.79±1.49 13 +
GL-8 11.08 ±3.73 2.12 ±1.08 19 +
ACNU
Epe-1 6.08 ±2.33 2.11 ± 0.67 35 +
GL-1 3.96±1.31 0.90± 0.18 23 +
GL-2 10.00±3.89 1.12±0.12 11 +
GL-3 10.69 ±3.54 2.85±1.11 27 +
GL-5 7.12±3.66 0.30±0.12 4 +
GL-7 12.29±4.13 0.07±0.03 1 +
GL-8 7.25 ± 1.99 0.46 ± 0.20 6 +
aRelative tumour volume (RV), RV=V4/VO, where VU is the tumour volume
on day 14 and V0 is the initial tumour volume when the treatment was started
(day 0). bT/C (%) values defined as the ratio of the RVof the treated tumour
xenografts to that of controls on day 14 after drug administration. cL4test,
statistical differences were determined by the Mann-Whitney U-test
(P< 0.01, one-sided; +, significant; -, insignificant). VCR, vincristine; DOX,
doxorubicin; ACNU, nimustine.
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Figure 1 Human multidrug resistance gene (MDR1) expression. MDR1
(243 bp) and human 032-microglobulin (H-P2m, 120 bp) were amplified by 26
cycles of PCR with a cDNA reverse transcribed from 500 ng of the total
cellular RNA. (A) MDR1 expression in the human and murine normal tissues.
Lane 1, human kidney; lane 2, murine kidney; lane 3, human brain; lane 4,
murine brain. (B) MDR1 expression in the human glioma transplanted
subcutaneously (scX) and intracerebrally (icX). Lane 1, KB8-5; lane 2,
KB 3-1; lane 3, GL-2 (scX); lane 4, GL-3 (scX); lane 5, GL-5 (scX); lane 6,
GL-8 (scX); lane 7, GL-2 (icX); lane 8, GL-5 (icX); lane 9, GL-8 (icX)
Table 3 In vivo chemotherapy of intracerebrally transplanted glioma
xenograft (icX)
Xenograft Survival days ILS
drug (%)
Control Treated
VCR
GL-2 32.2± 6.1 41.5 ± 2.8 29
GL-5 34.2 ± 4.2 45.2 ± 3.1 32
GL-8 28.0±3.6 32.3±2.1 15
DOX
GL-2 28.5 ± 4.9 44.3 ± 9.2 55
GL-5 37.7 ± 4.4 39.5 ± 6.1 5
GL-8 28.0 ± 3.6 36.7 ± 6.9 31
ACNU
GL-2 28.5 ± 4.9 97.2 ± 5.9 241a
GL-5 41.7 ± 5.6 99.0 ± 4.4 137a
GL-8 28.0 ± 3.6 80.5 ± 12.8 188a
aSignificant by Student's t-test (P < 0.01). ILS, increase in lifespan; VCR,
vincristine; DOX, doxorubicin; ACNU, nimustine.
Table 4 MDR1, mdr3gene and P-gp expression in icX and scX human glioma
Xenograft MDR18 mdr3b Pgpc
icX 0/3 3/3 3/3
scX 0/7 3/7d 0/7
a,bHuman multidrug resistance gene (MDR1) and murine mdr3 gene
expression were detected by reverse transcriptase polymerase chain reaction
assay. cThe expression of murine P-glycoprotein (P-gp) was detected only on
endothelial cells by immunohistochemical analysis. cThe levels of mdr3gene
expression in three scX were very faint (see Figure 2C). scX, xenografts
transplanted intracerebrally; icX, xenografts transplanted subcutaneously.
96% and 75% homology, respectively, with the murine mdr3 gene
(Figure IA). We thus avoided amplification of murine mdr gene
transcripts contaminating the tumour xenografts.
Neither human glioma scX nor icX expressed MDR] (Table 4,
Figure 1B). Colon and pancreatic cancer xenografts uniformly
retained levels of MDRJ gene expression similar to those in the
original carcinomas (data not shown).
Expression of murine mdr3 gene
Murine mdr3-specific amprimers did not amplify the human
MDRJ cDNA from normal human tissues (brain and kidney,
Figure 2A), although both sense and antisense primers revealed
67% homology with the human MDRJ gene. We thus specifically
determined murine mdr3 gene transcripts with these amprimers.
The amount of the PCR product of murine mdr3 was proportional
to the initial template cDNA reverse transcribed from mRNA
under ourexperimental conditions.
We quantitatively analysed the RT-PCR of mdr3 mRNA in
murine brain, according to the modifiedprocedures reported previ-
ously (Abe et al, 1993; 1994b). The specific mdr3 products were
also amplified exponentially by 22-32 PCR cycles (data not
shown). The results suggested that mdr3 gene expression can be
semiquantified by 28 cycles ofRT-PCR with 500 ng ofRNA. The
icX showed significantly stronger mdr3 expression than normal
murine brain (Figure 2B), whereas three ofseven scX showed only
faint levels ofmdr3 expression (Figure 2C).
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Figure 3 Localization of P-gp: immunohistochemical analysis was performed
with anti-P-gp polyclonal antibody Ab-1. Positive staining was observed at
the vessels in the intracerebrally (icX) transplanted glioma xenografts (GL-8,
right upper side) and the extraneoplastic brain tissue (left lower side) (x 100)
218bp : ; *----mr
100 bp
Figure 2 Murine multidrug-resistance gene (mdr3) expression. Specific PCR
products for mdr3 (218 bp) and for murine ,32-microgloburine (M-P2m, 100 bp)
were amplified by 26 cycles of PCR with a cDNA reverse transcribed from
500 ng. (A) mdr3 gene expression in the normal human (H) and murine (M)
tissues. Lane 1, M-kidney; lane 2, H-kidney; lane 3, M-brain; lane 4, H-brain;
lane 5, M-liver; lane 6, M-spleen; lane 7, M-heart; lane 8, M-skin. (B) The mdr3
gene expression in the human glioma transplanted intracerebrally (icX). Lane 1,
GL-2 (icX); lane 2, M-brain; lane 3, GL-5 (icX); lane 4, GL-8 (icX). (C) mdr3
gene expression in the human glioma transplanted subcutaneously (scX).
Lane 1, M-brain; lane 2, GL-2 (scX); lane 3, GL-5 (scX); lane 4, GL-8 (scX)
Localization of P-gp
We examined the localization ofP-gp in human glioma oficX and
scX. The localization ofP-gp was limited to the stromal vessels in
icX by immunohistochemistry (Figure 3), while the scX expressed
no P-gp (Table 4). P-gp was produced specifically on the capillary
blood vessels, whereas neither tumour nor normal glial cells
showed P-gp expression.
DISCUSSION
Human glioma usually shows intrinsic multidrug resistance to
various anti-cancer agents. The multidrug-resistance phenomenon of
gliomahas been explained by the presence ofthe BBB on the stromal
vessels. Chemotherapy with nitrosoureas, such as BCNU and
ACNU, has been shown to be effective in glioma, whereas such anti-
cancer drugs as VCR and DOX were not successful (Edwards et al,
1980; Komblith et al, 1988). Previous studies have indicated that
glioma xenografts, transplanted subcutaneously into host animals,
were uniformly sensitive to such anti-cancer drugs, as VCR, DOX
and ACNU in vivo (Maruo et al, 1990; Abe et al, 1994a).
In this study, we examined the drug sensitivity ofhuman glioma
scX and icX in vivo to examine the above discrepancy between the
clinical drug sensitivity ofglioma and the experimental drug sensi-
tivity of scX. The icX was relatively resistant to VCR and DOX
(ILS% < 55%), and was sensitive only to ACNU (ILS% 2 137%).
The icX reflected the clinical drug sensitivity ofglioma. However,
scX were sensitive to all three anti-cancer drugs (T/C% < 66%).
Several studies have indicated that P-gp constitutes part of the
BBB (Thiebaut et al, 1987), whereas some studies have shown that
the expression of P-gp is limited to stromal capillary endothelial
cells (Cordon-Cardo et al, 1989; Sugawara et al, 1990; Hegmann
et al, 1992, Tanaka et al, 1994). However, others have suggested
that P-gp overexpression in glioma cells contributes to MDR
(Matsumoto et al, 1991; Nabors et al, 1991; Becker et al, 1991).
Although these studies employed immunohistochemical methods
using anti-P-gp monoclonal antibodies, the localization and
apparent function of P-gp in the normal brain and glioma were in
conflict. P-gp or MDR] gene overexpression in solid tumour cells
is generally thought to be an essential mechanism of multidrug
resistance to hydrophobic anti-cancer agents (Gottesman et al,
1991). In the present study, neither the scX nor icX of human
glioma revealed MDR] expression by the RT-PCR assay. Murine
mdr3 expression was enhanced in the icX compared with the
normal murine brain, whereas the scX did not show significant
enhancement of mdr3 expression. By immunohistochemical
analysis, we confirmed limited P-gp expression not on tumour
cells, but on capillary blood vessel walls.
Replacement of the human cerebral stroma, including blood
vessels, by the murine subcutaneous stroma resulted in the loss of
MDR] expression in the human glioma xenografts (Tanaka et al,
1994). This molecular biological finding in glioma xenografts is
consistent with the limited localization on the endothelial cells
described above.
Murine mdr3 expression was enhanced in the icX compared
with the normal murine brain, whereas the scX did not show
significant enhancement ofmdr3 expression. Schinkel et al (1994)
reported that the expression of the murine mdr3 gene was prefer-
entially related to multidrug resistance in murine brain. We
confirmed that the level of mdr3 gene expression was higher than
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that of murine mdrl (also called mdrlb) in normal murine brain
and in human glioma xenografts (data not shown). Our results
support the idea that murine P-gp, encoded by mdr3, contributed to
the multidrug resistance ofthe human glioma icX in vivo.
The reversal ofP-gp function produced by anti-P-gp monoclonal
antibody, or by various compounds such as calcium channel
antagonists, calmodulin inhibitors and cyclosporins, has over-
come multidrug resistance in many tumours in vitro and in vivo
(Boesch et al, 1991; Kadam et al, 1992; Mickisch et al, 1992;
Miyamoto et al, 1993). The results presented here suggest that
glioma cells are themselves sensitive to VCR, DOX and ACNU,
and that circumvention of the BBB-like function of P-gp could
allow successful chemotherapy with these conventional anti-
cancer agents. The scX and icX systems of human glioma appear
to be useful models for study of the intrinsic multidrug resistance
ofglioma in vivo, and for studies ofways in which this multidrug
resistance can be overcome.
We did not examine the glioma or glioma xenografts after
chemotherapy, and it is unclear whether the overexpression of
P-gp is inducible in glioma tumour cells. Further analysis of P-gp
expression in xenografts after experimental treatment will provide
more information on the acquired multidrug resistance of glioma
in vivo.
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